SA518392179B1 - مركبات من مضاد لمستقبل سوماتوستاتين وطرق استخدامها - Google Patents

مركبات من مضاد لمستقبل سوماتوستاتين وطرق استخدامها

Info

Publication number
SA518392179B1
SA518392179B1 SA518392179A SA518392179A SA518392179B1 SA 518392179 B1 SA518392179 B1 SA 518392179B1 SA 518392179 A SA518392179 A SA 518392179A SA 518392179 A SA518392179 A SA 518392179A SA 518392179 B1 SA518392179 B1 SA 518392179B1
Authority
SA
Saudi Arabia
Prior art keywords
methods
same
receptor antagonist
somatostatin receptor
antagonist compounds
Prior art date
Application number
SA518392179A
Other languages
English (en)
Inventor
ستيفين بول ارنس
دافى جيريمى باوديليت
جيمس برين جاكويث
اريك روى سيمونسون
ناج شاروان كومار
ريتشارد توم ليجينس
توم هان هسياو هسى
Original Assignee
كدرد فينتوريس إنك
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by كدرد فينتوريس إنك filed Critical كدرد فينتوريس إنك
Publication of SA518392179B1 publication Critical patent/SA518392179B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات من مضاد antagonist لمستقبل سوماتوستاتين somatostatin لها الصيغة البنائية I: الصيغة I، تركيبات تشتمل عليها، وطرق استخدام المركبات والتركيبات المذكورة. يمكن أن تكون المركبات مفيدة في منع أو علاج انخفاض السكر في الدم hypoglycemia. [الشكل 3].
SA518392179A 2016-02-09 2018-08-09 مركبات من مضاد لمستقبل سوماتوستاتين وطرق استخدامها SA518392179B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662293216P 2016-02-09 2016-02-09
PCT/CA2017/050156 WO2017136943A1 (en) 2016-02-09 2017-02-09 Somatostatin receptor antagonist compounds and methods of using the same

Publications (1)

Publication Number Publication Date
SA518392179B1 true SA518392179B1 (ar) 2022-05-16

Family

ID=59562899

Family Applications (1)

Application Number Title Priority Date Filing Date
SA518392179A SA518392179B1 (ar) 2016-02-09 2018-08-09 مركبات من مضاد لمستقبل سوماتوستاتين وطرق استخدامها

Country Status (14)

Country Link
US (2) US11279732B2 (ar)
EP (1) EP3414259A4 (ar)
JP (3) JP6989529B2 (ar)
KR (1) KR20180117636A (ar)
CN (1) CN109104863A (ar)
AU (4) AU2017217271C1 (ar)
BR (1) BR112018016198A2 (ar)
CA (1) CA3013882A1 (ar)
IL (2) IL260851B (ar)
MX (2) MX2018009655A (ar)
RU (2) RU2020143060A (ar)
SA (1) SA518392179B1 (ar)
WO (1) WO2017136943A1 (ar)
ZA (1) ZA201805496B (ar)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017217271C1 (en) * 2016-02-09 2021-08-05 Cdrd Ventures Inc. Somatostatin receptor antagonist compounds and methods of using the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508711A (en) 1983-04-18 1985-04-02 American Cyanamid Company Cyclic pentapeptide displaying somatostatin antagonism and method of treatment of mammals therewith
CA2183421A1 (en) 1994-02-18 1995-08-24 John Mertens Labelled peptide compounds
US5663292A (en) 1994-12-12 1997-09-02 The Salk Institute For Biological Studies Cyclic CRF analogs
US5846934A (en) 1996-02-20 1998-12-08 American Cyanamid Company Pure somatostatin antagonist and methods of use thereof
RU2242481C2 (ru) 1998-06-16 2004-12-20 Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик Сас Аналоги циклического соматостатина
US7423177B2 (en) * 2001-03-05 2008-09-09 Transtech Pharma, Inc. Carboxamide derivatives as therapeutic agents
RU2263678C2 (ru) 2001-03-08 2005-11-10 Дзе Администрейторс Оф Дзе Тьюлейн Эдьюкейшнл Фанд Антагонисты соматостатина
US7019109B2 (en) 2001-03-16 2006-03-28 The Salk Institute For Bilogical Studies SSTR1-selective analogs
EP1283216A1 (en) 2001-08-10 2003-02-12 Mallinckrodt Inc. Somatostatin analogues binding to all somatostatin receptor subtypes and their use
IL160993A0 (en) 2001-09-21 2004-08-31 Univ Tulane Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
ES2312983T3 (es) 2003-03-19 2009-03-01 Universitatsspital Basel Conjugados radiomarcados basados en sustancia p y sus usos.
US8691761B2 (en) * 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
CN101631801B (zh) 2006-10-16 2013-06-05 索尔克生物学研究院 受体（sstr2）-选择性生长抑素拮抗剂
US7862825B2 (en) * 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
EP2168983A1 (fr) * 2008-09-30 2010-03-31 Ipsen Pharma Nouveaux composés octapeptidiques et leur utilisation thérapeutique
MX2011004504A (es) 2008-10-29 2011-06-16 Merck Sharp & Dohme Derivados de triazol beta carbolina como compuestos antidiabeticos.
AU2017217271C1 (en) * 2016-02-09 2021-08-05 Cdrd Ventures Inc. Somatostatin receptor antagonist compounds and methods of using the same

Also Published As

Publication number Publication date
EP3414259A1 (en) 2018-12-19
RU2018132050A3 (ar) 2020-06-02
IL260851A (en) 2018-10-31
MX2018009655A (es) 2019-05-22
JP2024009898A (ja) 2024-01-23
AU2017217271A1 (en) 2018-08-16
AU2017217271C1 (en) 2021-08-05
AU2024219610A1 (en) 2024-10-03
ZA201805496B (en) 2019-11-27
BR112018016198A2 (pt) 2019-01-22
RU2740464C2 (ru) 2021-01-14
MX2022016251A (es) 2023-02-09
AU2017217271B2 (en) 2021-03-25
CA3013882A1 (en) 2017-08-17
US20220112242A1 (en) 2022-04-14
IL284081A (en) 2021-07-29
US11279732B2 (en) 2022-03-22
EP3414259A4 (en) 2019-10-16
RU2020143060A (ru) 2021-02-20
IL260851B (en) 2021-07-29
JP2022046477A (ja) 2022-03-23
JP6989529B2 (ja) 2022-01-05
WO2017136943A1 (en) 2017-08-17
KR20180117636A (ko) 2018-10-29
AU2023201653A1 (en) 2023-04-13
CN109104863A (zh) 2018-12-28
AU2021204347A1 (en) 2021-07-29
JP2019508492A (ja) 2019-03-28
RU2018132050A (ru) 2020-03-10
US20190040102A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
MY196319A (en) Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders
MX2018009773A (es) Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
MX2018006217A (es) Agonistas del receptor de apelina y metodos de uso.
MD4635B1 (ro) Compuşi de chinolină substituiţi selectiv
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
MX2017001279A (es) Usos y composiciones de la flagelina.
EA201692316A1 (ru) Производные холана для применения при лечении и/или профилактике fxr и tgr5/gpbar1-опосредованных заболеваний
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
MD4650B1 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
MX2017000980A (es) Composiciones de tratamiento.
MX2017000976A (es) Composiciones de tratamiento.
MX2016011897A (es) Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.
WO2013169574A3 (en) Aliphatic spirolactam cgrp receptor antagonists
MX2013005246A (es) Antagonistas del receptor del peptido relacionado con el gen de calcitonina (cgrp) de piperidinona carboxamida azaindano.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2018015247A (es) Heterociclos de biarilmetilo.
JO3794B1 (ar) المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2018007084A (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)